Literature DB >> 7435812

Comparison of platelet adherence and aggregation in modified human umbilical vein and autogenous vein grafts.

L R Roedersheimer, R H Feins, S I Schwartz, J A DeWeese, R M Green.   

Abstract

The use of glutaraldehyde-tanned human umbilical vein as a vascular conduit has recently become popular. In previous studies in our laboratory, neointimal fibrous hyperplasia was responsible for poor long-term patency of this material in a canine model. The present study was undertaken to compare the platelet-adhering characteristics of autogenous vein and modified human umbilical vein. After platelets were labelled with chromium-51, 10 mongrel dogs underwent bilateral end-to-side femoral artery bypass grafts. Human umbilical vein and autogenous jugular vein were placed in opposing groins of each dog. Two hours after graft implantation, the animals were killed and the grafts retrieved along with 1 cm of the host artery at each anastomosis. These specimens and an aliquot of blood were placed in a scintillation counter and radioactivity levels were determined. The human umbilical vein had significantly more platelet adherence than the autogenous veins as determined by counts per gram per 10 minutes. The handling characteristics of human umbilical vein were also suboptimal. Separation of the graft layers was occasionally observed, sometimes resulting in intramural hematomas and graft dissection. The previously reported poor performance of human umbilical vein in the canine model is most likely a result of its platelet-adhering surface and poor handling characteristics.

Entities:  

Mesh:

Year:  1980        PMID: 7435812     DOI: 10.1016/0002-9610(80)90036-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Aspirin and dipyridamole reduce platelet deposition on prosthetic femoro-popliteal grafts in man.

Authors:  M D Goldman; D Simpson; R J Hawker; H C Norcott; C N McCollum
Journal:  Ann Surg       Date:  1983-12       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.